Altos Labs

$3B cellular-rejuvenation company built like a research institute; nearly five years in, still without a disclosed clinical candidate.

1. Core Product / Service

Altos Labs launched publicly on 19 January 2022 with $3B in committed capital, the largest launch in biotech history [1]. It is organised as institutes:

• Three Institutes of Science: Bay Area (Redwood City), San Diego, and Cambridge UK [1]
• An Institute of Medicine
• An Institute of Computation, opened in August 2024 [2]

Its scientific thesis is cellular rejuvenation programming: partial epigenetic reprogramming and related mechanisms that restore cell health and resilience.

As of October 2026 there is no disclosed IND, clinical candidate or Altos-sponsored trial, and a ClinicalTrials.gov sponsor search returns zero studies [2]. Steps towards the clinic:

• May 2025: acquired Dorian Therapeutics, a Stanford spinout with preclinical small-molecule "senoblockers" for lung fibrosis and osteoarthritis. Terms were not disclosed [2].
• August 2025: hired Joan Mannick (resTORbio, Tornado) as CMO and Head of Product Development [5].

2. Target Users & Pain Points

• Long-run target: age-related and degenerative diseases, where restoring cell function rather than blocking one pathway could address several conditions at once.
• Near-term: no product users. Its "customers" are effectively its own clinical development group and future partners.

3. Competitive Landscape

4. Unique Observations

• Wet lab at institute scale, with GMP manufacturing outsourced. Reported footprint across three sites:

  Site	Space	Detail
  Cambridge UK (Granta Park)	~51,000 sq ft, 10-year lease	Fit-out designed for ~150 researchers [3]
  San Diego	~123,000 sq ft built out across two buildings	~60% lab, including an 18,270 sq ft vivarium (contractor page) [4]
  Redwood City	Reported as anything from ~168,000 to ~250,000 sq ft	Sources conflict [2]

  That makes Altos's footprint several times the 50–90k sq ft typical of the 2023+ AI-bio cohort. Mid-2026 job postings describe in-house process development across mRNA-LNP, AAV and protein. The same postings describe "outsourced GMP manufacturing" with unnamed CDMOs [6].

• Modality breadth before the first IND. Altos is building process development for three biologic modalities while also holding small molecules from Dorian. Its first clinical asset may well be a conventional small molecule rather than a reprogramming therapy.

• Signs of a 2026 reshuffle. Founding Bay Area institute director Peter Walter moved to the Buck Institute in April 2026 [7], and other senior scientists have reportedly left. Infrastructure hiring (vivarium, process development) continued.

5. Financials / Funding

• Launch (January 2022): $3B committed. Reported backers include Yuri Milner, Jeff Bezos and ARCH's Robert Nelsen, though investor names were never formally confirmed [1].
• Aggregators describe a February 2024 "Series C" of $1.5B as a drawdown of the original commitment. Their cumulative totals ($3.3B to $5.6B) conflict and have not been verified [2].
• There is no SEC Form D on file and no reliable valuation.

6. People & Relationships

• CEO: Hal Barron (former GSK CSO and President, R&D) [1].
• Co-founders and co-chairs: Rick Klausner (Chief Scientist), Hans Bishop (President; ex-Juno CEO) [1].
• Institute leaders at launch: Peter Walter, Juan Carlos Izpisua Belmonte, Wolf Reik. Hana El-Samad leads the Institute of Computation [1][2].
• Peers: newlimit, retro-biosciences.

Sources

• [1] Altos Labs launch coverage, BioSpace / GEN, January 2022 (accessed 2026-10-14)
• [2] Research notes on US non-AI drug developers founded 2018–2022, 2026-10-14
• [3] BioMed Realty Granta Park lease release, BusinessWire, 2022-02-28 (accessed 2026-10-14)
• [4] Level 10 Construction project page, Altos San Diego tenant improvements (accessed 2026-10-14)
• [5] Altos Labs press release, Joan Mannick appointment, August 2025 (accessed 2026-10-14)
• [6] Altos Labs job posting, drug product process development, June 2026 (accessed 2026-10-14)
• [7] Buck Institute release on Peter Walter joining its faculty, April 2026 (accessed 2026-10-14)